Skip to main content

Economics of Personalized Medicine

  • Chapter
  • First Online:
Textbook of Personalized Medicine
  • 2363 Accesses

Abstract

Success of personalized medicine cannot be measured in dollars alone. The improvement in healthcare and quality of life with reduction of disease burden will have an impact on all aspects of human life with economic benefits. A discussion of financial aspects, of personalized medicine, however, is important for two reasons: (1) pharmaceutical companies would like to know if it would be profitable; and (2) healthcare providers would like to know if it is affordable. Development of personalized medicine would also affect the pharmaceutical markets, which are described in detail in a special report on this topic (Jain 2015a).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Behl AS, Goddard KA, Flottemesch TJ, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst. 2012;104:1785–95.

    Article  PubMed Central  PubMed  Google Scholar 

  • Jain KK. Personalized medicine: scientific & commercial aspects. Basel: Jain PharmaBiotech; 2015a.

    Google Scholar 

  • Jain KK. Molecular diagnostics: technologies, markets and companies. Basel: Jain PharmaBiotech; 2015b.

    Google Scholar 

  • O’Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health. 2013;16(6 Suppl):S1–3.

    Article  PubMed  Google Scholar 

  • Reid RJ, McBride CM, Alford SH, et al. Association between health-service use and multiplex genetic testing. Genet Med. 2012;14:852–9.

    Article  PubMed Central  PubMed  Google Scholar 

  • van Rooij T, Wilson DM, Marsh S. Personalized medicine policy challenges: measuring clinical utility at point of care. Expert Rev Pharmacoecon Outcomes Res. 2012;12:289–95.

    Article  PubMed  Google Scholar 

  • You A. Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother. 2011;12:435–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jain, K.K. (2015). Economics of Personalized Medicine. In: Textbook of Personalized Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2553-7_23

Download citation

Publish with us

Policies and ethics